Please assess the completion status of the following clinical trial:

Trial Title: Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological or cytological diagnosis of extensive stage small-cell lung cancer (ES-SCLC),\* including malignant pleural effusion~2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2~3. No prior systemic chemotherapy, immunotherapy, or biological therapy for SCLC~4. Measurable disease as defined by the RECIST criteria~5. Adequate organ function as defined by the protocol~6. Female patients of child bearing potential (CBP) must agree to use of reliable method of birth control during and for 3 months following treatment~7. Patients must sign informed consent document~8. Patients must be ≥ 18 years of age~9. Patients with brain metastases that have been adequately treated and are determined to be controlled by the attending physician are eligible~10. Patients who have had prior malignancies are eligible if they are ≥ 5 years from diagnosis free of disease or the attending physician believes the patient's prognosis is best defined by the ES-SCLC (if questions concerning this eligibility criteria arise, please contact the principal investigator)~(\*)ES-SCLC defined as metastases outside the chest, pulmonary metastases, or contralateral metastases (supraclavicular or hilar) nodes that could not be included with a reasonable single radiation port. Patients with malignant pleural effusions are considered extensive stage.~Exclusion Criteria:~1. Received treatment within the last 30 days with a drug that has not received Food and Drug Administration (FDA) approval for any indication at the time of study entry~2. Pregnancy or breast feeding~3. Serious active infection that would require a prolonged course (4-6 weeks) of antibiotics or would compromise the safety of the patient or compromise the patient's ability to complete the study~4. Symptomatic brain metastases~5. Grade ≥ 2 neuropathy using NCI CTCAE version 3.0 criteria~6. Previous anaphylactic reaction to carboplatin, paclitaxel, and docetaxel~7. Severe or uncontrolled cardiac disease, defined as uncontrolled or unstable angina, myocardial infarction in the last month, uncontrolled congestive heart failure (≥ 3 admissions for congestive heart failure in the 3 months prior to diagnosis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Carboplatin + Abraxane (240mg/m2) on Day 1 of a 21 Day cycle, up to 6 cycles
- Arm B (Type: EXPERIMENTAL): Carboplatin + Abraxane (80mg/m2)given on Days 1, 8 and 15 of a 21 Day Cycle, up to 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).